{"Symbol": "GLMD", "AssetType": "Common Stock", "Name": "Galmed Pharmaceuticals Ltd", "Description": "Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "16 Tiomkin Street, Tel Aviv, Israel, 6578317", "FullTimeEmployees": "17", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "106198896", "EBITDA": "-13835000", "PERatio": "None", "PEGRatio": "0", "BookValue": "2.831", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.585", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.216", "ReturnOnEquityTTM": "-0.3453", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-1.155", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "19.86", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "1.7628", "EVToRevenue": "0", "EVToEBITDA": "0.1251", "Beta": "2.4753", "52WeekHigh": "7.38", "52WeekLow": "3.02", "50DayMovingAverage": "4.7969", "200DayMovingAverage": "4.7194", "SharesOutstanding": "21113100", "SharesFloat": "12588884", "SharesShort": "465462", "SharesShortPriorMonth": "376027", "ShortRatio": "3.54", "ShortPercentOutstanding": "0.02", "ShortPercentFloat": "0.0251", "PercentInsiders": "21.357", "PercentInstitutions": "33.699", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}